Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Nature Communications|April 18, 2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Blood|July 31, 2024
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 studyOthman Al-Sawaf, Sandra Robrecht, Can Zhang, et al.
The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2025
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)Jeff P Sharman, Talha Munir, Sebastian Grosicki, et al.
International Journal of Cancer|November 18, 2018
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemiaNikos Papakonstantinou, Stavroula Ntoufa, Maria Tsagiopoulou, et al.
Blood|January 13, 2026
The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic LeukemiaOthman Al-Sawaf, Benjamin Nick Locher, Friederike Christen, et al.
Blood|March 22, 2014
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialStephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Pageof 8